ECB-ART-49487
Zhongguo Fei Ai Za Zhi
2020 Nov 20;2311:1014-1022. doi: 10.3779/j.issn.1009-3419.2020.101.44.
Show Gene links
Show Anatomy links
[Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].
Wang S
,
Shi Y
,
Han X
.
Abstract
Echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion accounts for 3%-5% of non-small cell lung cancer (NSCLC) patients. With the in-depth study of the EML4-ALK driver gene, ALK inhibitors represented by crizotinib have been gradually developed and applied in the clinic. However, the response to ALK-targeted therapy is heterogeneous among different patients. Most patients with ALK-targeted therapy will inevitably develop drug resistance, leading to tumor progression. Monitoring the efficacy of patients with prognostic markers to change the treatment in time, and selecting individualized follow-up treatment according to the mechanism of drug resistance, can effectively improve the prognosis of patients. This article will review the mechanism of ALK tyrosine kinase inhibitor (ALK-TKI) resistance and related prognostic markers to discuss the prediction for ALK-targeted therapy and the choice of subsequent treatment for drug-resistant patients. .
PubMed ID: 33203201
PMC ID: PMC7679215
Article link: Zhongguo Fei Ai Za Zhi
References [+] :
Ai,
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
2018, Pubmed
Ai, Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. 2018, Pubmed
Arai, Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. 2020, Pubmed
Awad, Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. 2017, Pubmed
Azzato, Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer. 2015, Pubmed
Cha, A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib. 2016, Pubmed
Chen, Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines. 2018, Pubmed
Choi, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. 2010, Pubmed , Echinobase
Couëtoux du Tertre, Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition. 2020, Pubmed
Crystal, Patient-derived models of acquired resistance can identify effective drug combinations for cancer. 2014, Pubmed
Dagogo-Jack, Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. 2019, Pubmed
Doebele, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. 2012, Pubmed
Dong, Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. 2016, Pubmed
Ettinger, NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. 2019, Pubmed
Fukuda, Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. 2019, Pubmed
Gainor, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. 2016, Pubmed
Garassino, Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 2018, Pubmed
Isozaki, Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. 2015, Pubmed , Echinobase
Isozaki, Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. 2016, Pubmed
Ji, Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. 2014, Pubmed
Kang, Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. 2018, Pubmed
Katayama, P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. 2016, Pubmed
Katayama, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. 2014, Pubmed
Katayama, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. 2011, Pubmed , Echinobase
Katayama, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 2012, Pubmed
Kim, Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. 2013, Pubmed
Kim, Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. 2013, Pubmed
Kim, Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. 2019, Pubmed
Kogita, Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. 2014, Pubmed , Echinobase
Kwok, Transfer of Extracellular Vesicle-Associated-RNAs Induces Drug Resistance in ALK-Translocated Lung Adenocarcinoma. 2019, Pubmed
Lai, miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. 2019, Pubmed , Echinobase
Liang, Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. 2019, Pubmed , Echinobase
Lin, Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. 2019, Pubmed
Lin, Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. 2018, Pubmed
Long, Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report. 2020, Pubmed
Lovly, Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. 2012, Pubmed
Lovly, Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. 2014, Pubmed
Ma, Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib. 2019, Pubmed
Matikas, Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer. 2016, Pubmed , Echinobase
Mengoli, K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. 2016, Pubmed
Nakamichi, Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. 2018, Pubmed
Okada, Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. 2019, Pubmed
Pailler, Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. 2017, Pubmed
Qin, Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. 2020, Pubmed
Recondo, Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. 2020, Pubmed
Recondo, Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? 2018, Pubmed
Redaelli, Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. 2018, Pubmed
Rihawi, MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. 2019, Pubmed
Sang, Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. 2013, Pubmed
Sasaki, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. 2010, Pubmed
Sasaki, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. 2011, Pubmed
Sharma, A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. 2019, Pubmed
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Shaw, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. 2013, Pubmed
Shaw, Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. 2016, Pubmed
Shaw, ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. 2019, Pubmed
Shrestha, Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. 2019, Pubmed
Takahashi, Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. 2020, Pubmed
Tong, Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. 2018, Pubmed
Tsuji, Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. 2019, Pubmed
Wei, Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers. 2018, Pubmed
Wilson, A functional landscape of resistance to ALK inhibition in lung cancer. 2015, Pubmed
Woo, Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. 2017, Pubmed , Echinobase
Yamada, Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. 2012, Pubmed
Yanagitani, Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. 2020, Pubmed
Yang, The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. 2020, Pubmed
Yoshida, Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. 2017, Pubmed
Yoshida, Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. 2016, Pubmed
Yu, Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. 2019, Pubmed
Yun, Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. 2018, Pubmed
Yun, Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. 2019, Pubmed
Zhang, Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. 2017, Pubmed
Zhang, Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report. 2018, Pubmed , Echinobase
Zhang, Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. 2020, Pubmed , Echinobase
Zheng, [Report of cancer epidemiology in China, 2015]. 2019, Pubmed